일본과 해외의 조사회사나 출판사로부터 출판된 산업 조사 보고서 및 데이터 판매 · 연간 서비스 · 맞춤 정보 제공 ChosaReport-Korea 주식회사 SEMABIZ

재생의학 (Regenerative Medicine) 시장조사 보고서

조사회사 : MarketsandMarkets (마켓츠앤마켓츠)   출판년월 : 2024년01월

Regenerative Medicine Market – Global Forecast to 2028

재생의학 시장 : 제품[줄기세포(자가, 동종), 면역요법, 유전자 치료, 조직공학], 용도(근골격, 암, 피부과, 상처치료, 심혈관질환, 안질환) – 2028년까지의 세계 예측
Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogenic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, Wound care, Cardiovascular Diseases, Eye Disorders) – Global Forecast to 2028

페이지 수 293
도표 수 306
구성 영문조사보고서
가격

    주문/문의    조사회사/구입안내

Report Overview

The global regenerative medicines market is projected to reach USD 49.0 Billion by 2028 from USD 16.0 Billion in 2023, at a CAGR of 25.1% during the forecast period of 2023 to 2028.

세계 재생의료 시장은 2023년부터 2028년까지 예측 기간 동안 연평균 성장률(CAGR) 25.1%로 성장해 2023년 160억 달러에서 2028년 490억 달러에 이를 것으로 예상됩니다.

Factors such as the wide scope in new therapeutic areas and collaborations and partnerships by major market players are predicted to uplift the market in the coming years. Additionally, rise in the focus of personalized medicine and rising regenerative medicine regulatory approvals will provide lucrative market growth. However, lack of long-term data and ethical and legal concerns and high cost of treatments are predicted to restrict the market.

재생의학 (Regenerative Medicine) 시장조사 보고서

“The cell therapy segment held the dominant share in the regenerative medicine market.”
Based on product, the global regenerative medicine market is segmented into gene therapy, cell therapy (stem cell therapy [cell transplantations, stem cell therapy products {autologous therapy, allogenic therapy] cell-based immunotherapy products), and tissue engineering products. The increasing popularity of stem therapy is expected to drive the expansion of the cell therapy market.

재생의학 (Regenerative Medicine) 시장조사 보고서 ecosystem

“Musculoskeletal disorders segment accounted for the largest share of the therapeutic area segment in 2022.”
Based on therapeutic area, the regenerative medicine market is segmented into oncology, musculoskeletal disorders, neurology, ophthalmology, dermatology & wound care, cardiovascular diseases, and other applications. This can be attributed to the increasing preavalence of orthopedic disorders and growing interest on musculoskeletal regeneration research.

“APAC region is likely to grow at a faster pace.”
The regenerative medicine market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. APAC region is anticipated to grow at a significant CAGR during the forecast period. High burden of chronic diseases, growing per capita income, and the rising demand for new technologies are expected to support regenerative medicine market growth in the region.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80%, and Demand Side – 20%
• By Designation (Supply Side): Managers – 45%, CXOs & Directors – 30%, Executives- 25%
• By Region: North America -55%, Europe -10%, Asia-Pacific -20%, Latin America -10%, MEA- 5%

재생의학 (Regenerative Medicine) 시장조사 보고서 region


List of Companies Profiled in the Report:
• Novartis AG (Switzerland)
• Biogen, Inc. (US)
• Sarepta Therapeutics, Inc. (US)
• Gilead Sciences, Inc. (US)
• Amgen Inc. (US)
• Smith+Nephew (UK)
• MEDIPOST Co., Ltd. (Korea)
• JCR Pharmaceuticals Co., Ltd. (Japan)
• Takeda Pharmaceutical Company Limited (Japan)
• CORESTEM, Inc (South Korea)
• Vericel Corporation (US)
• MIMEDX Group, Inc. (US)
• Organogenesis Inc. (US)
• Medtronic (Ireland)
• Bristol-Myers Squibb Company (US)
• Orthocell Ltd. (Australia)
• Mesoblast Ltd. (Australia)
• BioRestorative Therapies, Inc. (US)
• Pluristem Therapeutics Inc. (US)
• TEGOSCIENCE (South Korea)
• ANTEROGEN.CO.,LTD. (South Korea)
• Bluebird bio, Inc. (US)
• Stempeutics Research Pvt Ltd. (India)
• Sibiono GeneTech Co. Ltd. (China)
• Aspect Biosystems Ltd. (Canada)
• Athersys, Inc. (US)
Research Coverage:
This report provides a detailed picture of the regenerative medicine market. It aims to estimate the size and future growth potential of the market across different segments, such as product, therapeutic area and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Growing focus on personalized medicine, steep rise of regulatory approvals in regenerative medicine, rising collaborations and partnerships by major market players, increasing scope in new therapeutic areas), restraints (Lack of long-term data, Ethical and legal concerns and high cost of treatments), opportunities (Integration with artificial intelligence and big data, Harnessing the potential of 3D printing, Growing number of organ transplants) and challenges (Lack of favorable reimbursement policies across various regions) are influencing the growth of regenerative medicine market.
• Product Development/Innovation: Detailed insights on newly launched products of the regenerative medicine market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the regenerative medicine market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the regenerative medicine market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Smith+Nephew (UK), MEDIPOST Co., Ltd. (Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan) and CORESTEM, Inc (South Korea) and among others in the regenerative medicine market.

Table of Contents

1            INTRODUCTION            35

1.1         STUDY OBJECTIVES      35

1.2         MARKET DEFINITION   35

1.2.1      INCLUSIONS & EXCLUSIONS     36

1.3         MARKET SCOPE             36

1.3.1      MARKETS COVERED     36

1.3.2      YEARS CONSIDERED     37

1.3.3      CURRENCY CONSIDERED          37

1.4         RESEARCH LIMITATIONS           37

1.5         STAKEHOLDERS            38

1.6         SUMMARY OF CHANGES            38

1.7         IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET              39

2            RESEARCH METHODOLOGY     40

2.1         RESEARCH DATA           40

FIGURE 1           RESEARCH DESIGN       40

2.1.1      SECONDARY DATA       41

2.1.2      PRIMARY DATA 42

FIGURE 2           BREAKDOWN OF PRIMARIES: REGENERATIVE MEDICINE MARKET            42

2.2         MARKET SIZE ESTIMATION       43

FIGURE 3           MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS: REGENERATIVE MEDICINE MARKET, 2022          43

FIGURE 4           MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022              44

FIGURE 5           NOVARTIS AG: REVENUE SHARE ANALYSIS, 2022            44

FIGURE 6           PRODUCT-BASED REVENUE ANALYSIS, 2022     46

2.2.1      PRIMARY INSIGHTS       47

FIGURE 7           VALIDATION FROM PRIMARY EXPERTS 47

2.2.2      SEGMENT ASSESSMENT METHODOLOGY: REGENERATIVE MEDICINE MARKET            47

FIGURE 8           MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH       47

FIGURE 9           CAGR PROJECTIONS: REGENERATIVE MEDICINE MARKET              48

FIGURE 10         GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES IN REGENERATIVE MEDICINE MARKET  49

2.3         MARKET BREAKDOWN & DATA TRIANGULATION          50

FIGURE 11         DATA TRIANGULATION METHODOLOGY         50

2.4         STUDY ASSUMPTIONS  51

2.5         RISK ANALYSIS 51

2.6         IMPACT OF RECESSION ON REGENERATIVE MEDICINE MARKET              52

TABLE 1             GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH)         52

TABLE 2             US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)  53

TABLE 3             US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)  53

3            EXECUTIVE SUMMARY 54

FIGURE 12         REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)     54

FIGURE 13         REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)     55

FIGURE 14         GEOGRAPHICAL SNAPSHOT OF REGENERATIVE MEDICINE MARKET            56

4            PREMIUM INSIGHTS      57

4.1         REGENERATIVE MEDICINE MARKET OVERVIEW             57

FIGURE 15         FOCUS ON PERSONALISED MEDICINE TO DRIVE MARKET GROWTH          57

4.2         NORTH AMERICA: REGENERATIVE MEDICINE MARKET 58

FIGURE 16         CELL THERAPY TO COMMAND LARGEST SHARE OF NORTH AMERICAN REGENERATIVE MEDICINE MARKET             58

4.3         REGENERATIVE MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES           59

FIGURE 17         CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD              59

5            MARKET OVERVIEW     60

5.1         INTRODUCTION            60

5.2         MARKET DYNAMICS     60

FIGURE 18         REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    60

5.2.1      DRIVERS            61

5.2.1.1   Growing focus on personalized medicine       61

FIGURE 19         PERCENTAGE OF FDA APPROVALS FOR PERSONALIZED MEDICINE PRODUCTS (2018–2022)        61

5.2.1.2   Emerging applications in new therapeutic areas           62

TABLE 4             REGENERATIVE MEDICINE MARKET: EMERGING APPLICATIONS 63

5.2.1.3   Increasing collaborations and partnerships by major market players         64

5.2.1.4   Increasing regulatory approvals in regenerative medicine           65

TABLE 5             LIST OF KEY PRODUCT APPROVALS IN REGENERATIVE MEDICINE MARKET, 2021–2023 65

5.2.2      RESTRAINTS     66

5.2.2.1   Lack of long-term data       66

5.2.2.2   Ethical and legal concerns and high cost of treatments 66

5.2.3      OPPORTUNITIES           67

5.2.3.1   Harnessing the potential of 3D printing         67

5.2.3.2   Integration with artificial intelligence and big data       68

5.2.3.3   Growing number of organ transplants            68

5.2.4      CHALLENGES   69

5.2.4.1   Lack of favorable reimbursement policies across various regions 69

5.3         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 70

FIGURE 20         REVENUE SHIFT TOWARD REGENERATIVE MEDICINE COMPANIES      71

5.4         PRICING ANALYSIS        71

5.4.1      AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT              71

TABLE 6             REGENERATIVE MEDICINE PRICE TREND          71

5.5         SUPPLY CHAIN ANALYSIS          72

FIGURE 21         SUPPLY CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET              73

5.6         VALUE CHAIN ANALYSIS            73

FIGURE 22         VALUE CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET              74

5.7         ECOSYSTEM ANALYSIS 74

FIGURE 23         REGENERATIVE MEDICINE MARKET: ECOSYSTEM ANALYSIS              74

TABLE 7             ROLE IN ECOSYSTEM    74

5.8         TECHNOLOGY ANALYSIS           76

FIGURE 24         KEY STEPS IN GENE THERAPY  76

TABLE 8             STEM CELL THERAPIES AND GENE THERAPIES 76

5.9         PATENT ANALYSIS        78

TABLE 9             REGENERATIVE MEDICINE MARKET: INDICATIVE LIST OF PATENTS           79

5.10       KEY CONFERENCES & EVENTS IN 2024–2025       81

5.10.1    REGENERATIVE MEDICINE CONFERENCES IN 2024–2025             81

TABLE 10           REGENERATIVE MEDICINE CONFERENCES IN 2024–2025              81

5.11       TARIFF & REGULATORY LANDSCAPE    82

5.11.1    FDA APPROVALS           82

5.11.2    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          83

TABLE 11           NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         83

TABLE 12           EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83

TABLE 13           ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         85

TABLE 14           REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         86

5.12       PORTER’S FIVE FORCES ANALYSIS         87

TABLE 15           REGENERATIVE MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS          87

5.12.1    THREAT OF NEW ENTRANTS    87

5.12.2    THREAT OF SUBSTITUTES         87

5.12.3    BARGAINING POWER OF BUYERS           88

5.12.4    BARGAINING POWER OF SUPPLIERS     88

5.12.5    DEGREE OF COMPETITION       88

5.13       KEY STAKEHOLDERS & BUYING CRITERIA          89

5.13.1    KEY STAKEHOLDERS IN BUYING PROCESS         89

FIGURE 25         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF REGENERATIVE MEDICINE PRODUCTS 89

5.13.2    BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS 89

FIGURE 26         KEY BUYING CRITERIA FOR END USERS              89

5.14       PIPELINE ANALYSIS      90

TABLE 16           GENE THERAPY PRODUCTS UNDER CLINICAL TRIAL    90

TABLE 17           CELL THERAPY PRODUCTS UNDER CLINICAL TRIAL    93

6            REGENERATIVE MEDICINE MARKET, BY PRODUCT       94

6.1         INTRODUCTION            95

TABLE 18           REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 95

6.2         CELL THERAPY 95

TABLE 19           REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)             96

TABLE 20           REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION, 2021–2028 (USD MILLION)       96

TABLE 21           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)           97

TABLE 22           EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)       97

TABLE 23           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)       98

TABLE 24           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)           98

6.2.1      STEM CELL THERAPY   98

TABLE 25          REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)       99

TABLE 26          REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY REGION, 2021–2028 (USD MILLION)  99

TABLE 27           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 100

TABLE 28           EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)       100

TABLE 29           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)           101

TABLE 30           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 101

6.2.1.1   Cell transplantations          101

6.2.1.1.1 Potential of Allo-SCT in treating AML to drive segmental growth            101

TABLE 31           REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2021–2028 (USD MILLION)   102

TABLE 32           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)   102

TABLE 33           EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 103

TABLE 34           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 103

TABLE 35           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2021–2028 (USD MILLION)   104

6.2.1.2   Stem cell therapy products 104

TABLE 36           REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)             104

TABLE 37           REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY REGION, 2021–2028 (USD MILLION)        105

TABLE 38           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)              105

TABLE 39           EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 106

TABLE 40           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)   106

TABLE 41           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)              107

6.2.1.2.1 Autologous therapy           107

6.2.1.2.1.1           Low risk of post-treatment complications to support segment growth              107

TABLE 42           REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2021–2028 (USD MILLION)           108

TABLE 43           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)       108

TABLE 44           EUROPE: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)       109

TABLE 45           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)       109

TABLE 46           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)       110

6.2.1.2.2 Allogeneic therapy             110

6.2.1.2.2.1           High potential in disease treatment to ensure demand and development              110

TABLE 47           REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2021–2028 (USD MILLION)           111

TABLE 48           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)          111

TABLE 49           EUROPE: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)          112

TABLE 50           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)          112

TABLE 51           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)          113

6.2.2      CELL-BASED IMMUNOTHERAPY            113

6.2.2.1   Growing adoption of T-cell therapy in cancer treatment to support market growth              113

TABLE 52           REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY REGION, 2021–2028 (USD MILLION)        114

TABLE 53           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)              114

TABLE 54           EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)     115

TABLE 55           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)     115

TABLE 56           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)              116

6.3         GENE THERAPY             116

6.3.1      STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET    116

TABLE 57           APPROVED GENE THERAPIES, 2022       117

TABLE 58           REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)       117

TABLE 59           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)          118

TABLE 60           EUROPE: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)       118

TABLE 61           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)       119

TABLE 62           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)          119

6.4         TISSUE ENGINEERING  119

6.4.1      HIGH DEMAND FOR TISSUE ENGINEERING PRODUCTS IN DERMATOLOGY & WOUND CARE APPLICATIONS TO DRIVE MARKET   119

TABLE 63           REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2021–2028 (USD MILLION)  120

TABLE 64           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)             121

TABLE 65           EUROPE: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)            121

TABLE 66           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)            122

TABLE 67           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2021–2028 (USD MILLION)             122

7            REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA   123

7.1         INTRODUCTION            124

TABLE 68           NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS, BY THERAPEUTIC AREA, 2021 VS. 2022        124

TABLE 69           REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)          125

7.2         ONCOLOGY      125

7.2.1      INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET     125

TABLE 70           INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS    126

TABLE 71           REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)       128

TABLE 72           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)  128

TABLE 73           EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)  129

TABLE 74           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)  129

TABLE 75           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)  130

7.3         MUSCULOSKELETAL DISORDERS          130

7.3.1      RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET            130

TABLE 76           REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)       131

TABLE 77           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)              131

TABLE 78           EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)              132

TABLE 79           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)              132

TABLE 80           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION)              133

7.4         DERMATOLOGY & WOUND CARE          133

7.4.1      RISING USE OF WOUND CARE BIOLOGICS TO DRIVE MARKET  133

TABLE 81           INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS 134

TABLE 82           REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2021–2028 (USD MILLION)  134

TABLE 83           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)              135

TABLE 84           EUROPE: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)              135

TABLE 85           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)              136

TABLE 86           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2021–2028 (USD MILLION)              136

7.5         CARDIOVASCULAR DISEASES   136

7.5.1      INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO SUPPORT MARKET GROWTH    136

TABLE 87           REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)           137

TABLE 88           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 138

TABLE 89           EUROPE: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 138

TABLE 90           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 139

TABLE 91           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 139

7.6         OPHTHALMOLOGY      139

7.6.1      REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH          139

TABLE 92           LIST OF PIPELINE PRODUCTS FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY 140

TABLE 93           REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION)  141

TABLE 94           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)   141

TABLE 95           EUROPE: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)   142

TABLE 96           ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)   142

TABLE 97           LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)   143

7.7         NEUROLOGY    143

7.7.1      GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH  143

TABLE 98           REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)       144

TABLE 99           NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 144

TABLE 100         EUROPE: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 145

TABLE 101         ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 145

TABLE 102         LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 146

7.8         OTHER THERAPEUTIC AREAS   146

TABLE 103         REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)   147

TABLE 104         NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)              147

TABLE 105         EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)             148

TABLE 106         ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)              148

TABLE 107         LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION)              149

8            REGENERATIVE MEDICINE MARKET, BY REGION           150

8.1         INTRODUCTION            151

FIGURE 27         NUMBER OF PLAYERS IN REGENERATIVE MEDICINE MARKET, BY REGION, 2020–2022  151

TABLE 108         NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE (2022)   151

TABLE 109         REGENERATIVE MEDICINE MARKET, BY REGION, 2021–2028 (USD MILLION) 152

8.2         NORTH AMERICA          152

FIGURE 28         NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT        153

TABLE 110         NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    153

TABLE 111         NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   154

TABLE 112         NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)      154

TABLE 113         NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)         154

TABLE 114         NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 155

TABLE 115         NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             155

8.2.1      US         156

8.2.1.1   Rising number of pipeline products for regenerative medicine to drive market              156

TABLE 116         US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)     157

TABLE 117         US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)       157

TABLE 118         US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  158

TABLE 119         US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)         158

TABLE 120         US: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)            159

8.2.2      CANADA            159

8.2.2.1   Rising government initiatives for regenerative medicine research to drive market              159

TABLE 121         CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          160

TABLE 122         CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  161

TABLE 123         CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  161

TABLE 124         CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)         161

TABLE 125         CANADA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             162

8.2.3      NORTH AMERICA: RECESSION IMPACT 162

8.3         EUROPE             163

TABLE 126         EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          163

TABLE 127         EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          164

TABLE 128         EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  164

TABLE 129         EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  164

TABLE 130         EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)         165

TABLE 131         EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             165

8.3.1      GERMANY         166

8.3.1.1   Rising focus on clinical research and patent approvals to drive market     166

TABLE 132         GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          166

TABLE 133         GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  167

TABLE 134         GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)      167

TABLE 135         GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)            167

TABLE 136         GERMANY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             168

8.3.2      UK         168

8.3.2.1   Incorporating regenerative medicine into commercial healthcare services under NHS to drive market          168

TABLE 137         UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)     169

TABLE 138         UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)       169

TABLE 139         UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  170

TABLE 140         UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)         170

TABLE 141         UK: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)            171

8.3.3      FRANCE             171

8.3.3.1   Structured regulatory framework to drive regenerative medicine product pipeline              171

TABLE 142         FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          172

TABLE 143         FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  172

TABLE 144         FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  172

TABLE 145         FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)         173

TABLE 146         FRANCE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             173

8.3.4      ITALY   173

8.3.4.1   Rising prevalence of neurological and cardiovascular disorders to drive market              173

TABLE 147         ITALY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          174

TABLE 148         ITALY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  175

TABLE 149         ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  175

TABLE 150         ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)         175

TABLE 151         ITALY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)            176

8.3.5      SPAIN   176

8.3.5.1   Favorable regulatory environment to drive product pipeline       176

TABLE 152         SPAIN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          177

TABLE 153         SPAIN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  177

TABLE 154         SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  178

TABLE 155         SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)         178

TABLE 156         SPAIN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)            179

8.3.6      REST OF EUROPE           179

TABLE 157         REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   180

TABLE 158         REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)      180

TABLE 159         REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)         180

TABLE 160         REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 181

TABLE 161         REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             181

8.3.7      EUROPE: RECESSION IMPACT   182

8.4         ASIA PACIFIC    182

FIGURE 29         ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT              183

TABLE 162         ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    184

TABLE 163         ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   184

TABLE 164         ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  185

TABLE 165         ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)      185

TABLE 166         ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)            185

TABLE 167         ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             186

8.4.1      CHINA  186

8.4.1.1   Favorable government support for development of regenerative medicine to drive market   186

TABLE 168         CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          187

TABLE 169         CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  187

TABLE 170         CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  188

TABLE 171         CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)         188

TABLE 172         CHINA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             189

8.4.2      JAPAN  189

8.4.2.1   Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies          189

TABLE 173         JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT,

2021–2028 (USD MILLION)          190

TABLE 174         JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  190

TABLE 175         JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  191

TABLE 176         JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)         191

TABLE 177         JAPAN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA,

2021–2028 (USD MILLION)          192

8.4.3      INDIA   192

8.4.3.1   Introduction of novel therapies for CVD and cancer to support market growth              192

TABLE 178         INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,

2021–2028 (USD MILLION)          193

TABLE 179         INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  193

TABLE 180         INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  193

TABLE 181         INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)         194

TABLE 182         INDIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)            194

8.4.4      SOUTH KOREA 194

8.4.4.1   Strong research base and availability of funds to support market growth  194

TABLE 183         SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   195

TABLE 184         SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  196

TABLE 185         SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)         196

TABLE 186         SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 196

TABLE 187         SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             197

8.4.5      AUSTRALIA       197

8.4.5.1   Increasing incidence of sports injuries to support market growth             197

TABLE 188         AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   198

TABLE 189         AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  198

TABLE 190         AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)      198

TABLE 191         AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)            199

TABLE 192         AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             199

8.4.6      REST OF ASIA PACIFIC  199

TABLE 193         REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)            200

TABLE 194         REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)           200

TABLE 195         REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 200

TABLE 196         REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)              201

TABLE 197         REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)        201

8.4.7      ASIA PACIFIC: RECESSION IMPACT        201

8.5         LATIN AMERICA             202

TABLE 198         LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    202

TABLE 199         LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   203

TABLE 200         LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)      203

TABLE 201         LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)         203

TABLE 202         LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION) 204

TABLE 203         LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             204

8.5.1      BRAZIL 204

8.5.1.1   Gradual increase in pharmaceutical R&D to support market growth         204

TABLE 204         BRAZIL: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          205

TABLE 205         BRAZIL: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  205

TABLE 206         BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  205

TABLE 207         BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)         206

TABLE 208         BRAZIL: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             206

8.5.2      REST OF LATIN AMERICA          206

TABLE 209        REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2021–2028 (USD MILLION)            207

TABLE 210         REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)           207

TABLE 211         REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION) 208

TABLE 212         REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)              208

TABLE 213        REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)        209

8.5.3      LATIN AMERICA: RECESSION IMPACT   209

8.6         MIDDLE EAST  210

8.6.1      GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS           210

TABLE 214         MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY PRODUCT,

2021–2028 (USD MILLION)          210

TABLE 215         MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  211

TABLE 216         MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)      211

TABLE 217         MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)            211

TABLE 218         MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             212

8.6.2      MIDDLE EAST: RECESSION IMPACT       212

8.7         AFRICA 213

8.7.1      GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS  213

TABLE 219         AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT,

2021–2028 (USD MILLION)          213

TABLE 220         AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2021–2028 (USD MILLION)  213

TABLE 221         AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY,

BY TYPE, 2021–2028 (USD MILLION)       214

TABLE 222         AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)         214

TABLE 223         AFRICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)             215

8.7.2      AFRICA: RECESSION IMPACT     215

9            COMPETITIVE LANDSCAPE       216

9.1         INTRODUCTION            216

9.2         RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS        216

TABLE 224         REGENERATIVE MEDICINE MARKET: STRATEGIES ADOPTED BY KEY PLAYERS            216

9.3         REVENUE SHARE ANALYSIS       219

FIGURE 30         REVENUE ANALYSIS OF KEY PLAYERS (2020–2022)          219

9.4         MARKET SHARE ANALYSIS         219

FIGURE 31         MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)        220

TABLE 225         REGENERATIVE MEDICINE MARKET: DEGREE OF COMPETITION 220

9.5         COMPANY EVALUATION MATRIX          221

9.5.1      STARS  222

9.5.2      EMERGING LEADERS    222

9.5.3      PERVASIVE PLAYERS     222

9.5.4      PARTICIPANTS 222

FIGURE 32         REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX, 2022    223

9.5.5      COMPANY FOOTPRINT ANALYSIS         224

TABLE 226         REGENERATIVE MEDICINE MARKET: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS       224

TABLE 227         REGENERATIVE MEDICINE MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS       225

9.6         START-UP/SME EVALUATION MATRIX 226

9.6.1      PROGRESSIVE COMPANIES       226

9.6.2      RESPONSIVE COMPANIES          226

9.6.3      DYNAMIC COMPANIES 226

9.6.4      STARTING BLOCKS       226

FIGURE 33         REGENERATIVE MEDICINE MARKET: START-UP/SME EVALUATION MATRIX, 2022      227

9.6.5      COMPETITIVE BENCHMARKING            228

TABLE 228         REGENERATIVE MEDICINE MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS           228

TABLE 229         REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 229

9.7         COMPETITIVE SCENARIO & TRENDS     230

9.7.1      PRODUCT LAUNCHES  230

TABLE 230         REGENERATIVE MEDICINE MARKET: PRODUCT APPROVALS/LAUNCHES, JANUARY 2020 TO DECEMBER 2023     230

9.7.2      DEALS  233

TABLE 231         REGENERATIVE MEDICINE MARKET: DEALS, JANUARY 2020 TO DECEMBER 2023            233

9.7.3      OTHER DEVELOPMENTS           237

TABLE 232         REGENERATIVE MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2020 TO DECEMBER 2023        237

10          COMPANY PROFILES    239

10.1       KEY MARKET PLAYERS 239

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

10.1.1    NOVARTIS AG   239

TABLE 233         NOVARTIS AG: COMPANY OVERVIEW   239

FIGURE 34         NOVARTIS AG: COMPANY SNAPSHOT (2022)     240

10.1.2    BIOGEN INC.     244

TABLE 234         BIOGEN INC.: COMPANY OVERVIEW     244

FIGURE 35         BIOGEN INC.: COMPANY SNAPSHOT (2022)       245

10.1.3    GILEAD SCIENCES, INC. 248

TABLE 235         GILEAD SCIENCES, INC.: COMPANY OVERVIEW 248

FIGURE 36         GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)  249

10.1.4    SAREPTA THERAPEUTICS, INC. 253

TABLE 236         SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW 253

FIGURE 37         SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2022)              253

10.1.5    AMGEN, INC.     256

TABLE 237         AMGEN, INC.: COMPANY OVERVIEW     256

FIGURE 38         AMGEN, INC.: COMPANY SNAPSHOT (2022)       257

10.1.6    SMITH+NEPHEW           259

TABLE 238         SMITH+NEPHEW: COMPANY OVERVIEW            259

FIGURE 39         SMITH+NEPHEW: COMPANY SNAPSHOT (2022) 260

10.1.7    MEDIPOST CO., LTD.    262

TABLE 239         MEDIPOST CO., LTD.: COMPANY OVERVIEW     262

FIGURE 40         MEDIPOST CO., LTD.: COMPANY SNAPSHOT    262

10.1.8    JCR PHARMACEUTICALS CO., LTD.        265

TABLE 240         JCR PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW              265

FIGURE 41         JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2022)   265

10.1.9    TAKEDA PHARMACEUTICAL COMPANY LIMITED          267

TABLE 241         TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW        267

FIGURE 42         TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)          268

10.1.10  CORESTEM, INC.            270

TABLE 242         CORESTEM, INC.: COMPANY OVERVIEW            270

FIGURE 43         CORESTEM, INC.: COMPANY SNAPSHOT (2021) 270

10.1.11  VERICEL CORPORATION           272

TABLE 243         VERICEL CORPORATION: COMPANY OVERVIEW            272

FIGURE 44         VERICEL CORPORATION: COMPANY SNAPSHOT (2022) 272

10.1.12  MIMEDX GROUP, INC.   274

TABLE 244         MIMEDX GROUP, INC.: COMPANY OVERVIEW   274

FIGURE 45         MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2022)     274

10.1.13  ORGANOGENESIS INC. 278

TABLE 245         ORGANOGENESIS INC.: COMPANY OVERVIEW  278

FIGURE 46         ORGANOGENESIS INC.: COMPANY SNAPSHOT (2022)    278

10.1.14  MEDTRONIC     281

TABLE 246         MEDTRONIC: COMPANY OVERVIEW     281

FIGURE 47         MEDTRONIC: COMPANY SNAPSHOT (2022)       282

10.1.15  BRISTOL-MYERS SQUIBB COMPANY      284

TABLE 247         BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW              284

FIGURE 48         BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2022)   285

10.2       OTHER PLAYERS           288

10.2.1    ORTHOCELL LTD.         288

TABLE 248         ORTHOCELL LTD.: COMPANY OVERVIEW          288

10.2.2    MESOBLAST LTD.          289

TABLE 249         MESOBLAST LTD.: COMPANY OVERVIEW          289

10.2.3    BIORESTORATIVE THERAPIES, INC.       290

TABLE 250         BIORESTORATIVE THERAPIES, INC.: COMPANY OVERVIEW              290

10.2.4    PLURISTEM THERAPEUTICS INC.           290

TABLE 251         PLURISTEM THERAPEUTICS INC.: COMPANY OVERVIEW              290

10.2.5    TEGOSCIENCE 291

TABLE 252         TEGOSCIENCE: COMPANY OVERVIEW  291

10.2.6    ANTEROGEN.CO.,LTD. 292

TABLE 253         ANTEROGEN.CO.,LTD.: COMPANY OVERVIEW  292

10.2.7    BLUEBIRD BIO, INC.      293

TABLE 254         BLUEBIRD BIO, INC.: COMPANY OVERVIEW       293

10.2.8    STEMPEUTICS RESEARCH PVT. LTD.     294

TABLE 255         STEMPEUTICS RESEARCH PVT. LTD.: COMPANY OVERVIEW              294

10.2.9    SIBIONO GENETECH CO. LTD.  294

TABLE 256         SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW  294

10.2.10  ASPECT BIOSYSTEMS   295

TABLE 257         ASPECT BIOSYSTEMS: COMPANY OVERVIEW    295

TABLE 258         ATHERSYS, INC.: COMPANY OVERVIEW 296

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11          APPENDIX         297

11.1       DISCUSSION GUIDE      297

11.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             300

11.3       CUSTOMIZATION OPTIONS      302

11.4       RELATED REPORTS       302

11.5       AUTHOR DETAILS         303


    주문/문의폼

    • 리포트 제목은 자동으로 입력됩니다.

    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com